Comparative Pharmacology
Head-to-head clinical analysis: GENTAMICIN SULFATE versus NEBCIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GENTAMICIN SULFATE versus NEBCIN.
GENTAMICIN SULFATE vs NEBCIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of mRNA and inhibiting protein synthesis. Also disrupts bacterial cell membrane integrity.
Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of mRNA and inhibiting bacterial protein synthesis.
1-2 mg/kg IV every 8 hours or 3-5 mg/kg IV every 24 hours for extended-interval dosing; typical duration 7-10 days.
3-6 mg/kg/day IV in 2-3 divided doses every 8-12 hours; adjust based on serum levels and renal function.
None Documented
None Documented
Terminal elimination half-life: 2-4 hours in patients with normal renal function; prolonged to 24-72 hours in renal impairment.
Terminal elimination half-life is 2-3 hours in patients with normal renal function. Prolonged to 24-48 hours in anuria. Clinical context: Dosing interval adjustment required in renal impairment to avoid toxicity.
Renal excretion of unchanged drug accounts for >90% of elimination; biliary/fecal <2%.
Renal excretion of unchanged drug accounts for >90% of elimination. Approximately 10% is excreted in bile.
Category D/X
Category C
Aminoglycoside Antibiotic
Aminoglycoside Antibiotic